Tecvayli

RSS

Authorised

This medicine is authorised for use in the European Union

teclistamab
MedicineHumanAuthorised

Danish is available via eTranslation, the European Commission's machine translation service.

Translate to Danish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

Tecvayli is a cancer medicine used to treat multiple myeloma (a cancer of the bone marrow) that has come back or not responded to previous treatment. It can be used on its own or together with daratumumab (another cancer medicine) in adults who have received at least one previous treatment.

Tecvayli contains the active substance teclistamab.

Tecvayli can only be obtained with a prescription and treatment must be started and monitored by a doctor experienced in the management of multiple myeloma. It must be given in a facility with appropriate medical support to manage severe side effects such as cytokine release syndrome (a potentially life-threatening condition that causes fever, vomiting, shortness of breath, headache and low blood pressure).

Tecvayli is given as an injection under the skin. When used on its own, treatment starts with injections on days 1, 3 and 5 at increasing doses (so-called step-up dosing). Tecvayli is then given once a week up to week 8, once every two weeks from week 9 to week 24 and once every four weeks from week 25 onwards. Patients whose cancer has responded well to treatment should move earlier (before week 25) to injections once every 4 weeks.

When used in combination with daratumumab, only daratumumab is given on day 1. Treatment with Tecvayli starts with a step-up dosing schedule: injections of Tecvayli are given at increasing doses on days 2, 4 and 8. Treatment is then given once a week from weeks 3 to 8, every 2 weeks from weeks 9 to 24 and every 4 weeks from week 25 onwards.

One to three hours before receiving the injections that are given as part of the step-up dosing schedule, patients are given medicines to reduce the risk of developing cytokine release syndrome. Treatment can continue until the disease gets worse or the patient experiences unacceptable side effects.

For more information about using Tecvayli, see the package leaflet or contact your doctor or pharmacist.

The active substance in Tecvayli is teclistamab, an antibody (a type of protein) that is designed to recognise and attach to two targets simultaneously: the B cell maturation antigen (BCMA) on myeloma cells and CD3 on the surface of T cells (cells in the immune system). By attaching to these target proteins, this medicine brings the cancer cells and T cells together. This activates the T cells, which then kill the multiple myeloma cells.

The benefits of Tecvayli have been investigated in an ongoing study involving 165 patients with multiple myeloma who had received at least three prior treatments (including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody) and whose disease had not improved (refractory) or had come back (relapsed) after the last treatment. The study did not compare Tecvayli with other medicines or placebo (a dummy treatment). In this study, 63% (104 out of 165) of patients responded to treatment with Tecvayli and they lived for a median of 18 months without their disease getting worse.

Another main study involved 587 adults with multiple myeloma whose cancer had worsened after at least one previous treatment (including a proteasome inhibitor and lenalidomide, a type of immunomodulatory agent). The study compared Tecvayli given together with daratumumab with daratumumab given with either bortezomib or pomalidomide (other cancer medicines) and dexamethasone. The main measure of effectiveness was how long patients lived without their cancer getting worse. Based on the available data, after 36 months of treatment, around 83% of patients who received treatment with Tecvayli and daratumumab were alive without their disease getting worse compared with around 30% of patients who received daratumumab given with either bortezomib or pomalidomide and dexamethasone. In addition, after 36 months of treatment around 83% of those who received treatment with Tecvayli and daratumumab were alive compared with around 65% of those who received daratumumab given with either bortezomib or pomalidomide and dexamethasone. 

In another study involving 593 patients with multiple myeloma who had received one to three previous treatments, including lenalidomide and an anti-CD38 antibody, Tecvayli was compared with standard treatment (pomalidomide, bortezomib and dexamethasone or carfilzomib and dexamethasone). In this study, around 70 % of patients receiving Tecvayli did not experience a worsening of their disease or died compared with 36% of patients receiving standard treatment. After a median time of treatment of about 17 months, more than half of the patients receiving Tecvayli were still living without their disease getting worse, compared with a median of 8 months for patients receiving standard treatment. Patients receiving Tecvayli were also more likely to be alive at the time of the analysis. Studies carried out with Tecvayli are described in more detail in the medicine’s assessment reports. 

For the full list of side effects and restrictions of Tecvayli, see the package leaflet.

The most common side effects with Tecvayli (which may affect more than 1 in 10 people) include hypogammaglobulinaemia (low immunoglobulin or antibody levels in the blood, which increases the risk of infection), cytokine release syndrome, neutropenia (low levels of neutrophils, a type of white blood cell that fights infection), anaemia (low levels of red blood cells or haemoglobin), pain in the muscles and bones, tiredness, thrombocytopenia (low levels of blood platelets, components that help the blood to clot), injection site reactions, upper respiratory tract (nose and throat) infection, lymphopenia (low levels of lymphocytes, a type of white blood cell), diarrhoea, pneumonia (infection of the lungs), COVID-19, nausea (feeling sick), fever, headache, cough, pain and hypokalaemia (low blood potassium levels).

Some side effects can be serious. The most frequent (which may affect more than 1 in 10 people) include pneumonia, COVID-19 and cytokine release syndrome. Upper respiratory tract infection, sepsis (blood poisoning; when bacteria and their toxins circulate in the blood, leading to organ damage), fever, pain in the muscles and bones, diarrhoea and febrile neutropenia (low levels of neutrophils with fever) may affect up to 1 in 10 people.

At the time of approval, treatment options were limited for patients with multiple myeloma once previous treatments had stopped working. Tecvayli addressed a medical need in these patients and showed a clinically relevant treatment effect.

Compared with other daratumumab-based treatments, Tecvayli used with daratumumab helped patients live longer without their multiple myeloma getting worse and also increased how long patients lived overall. Tecvayli and daratumumab work in different ways to target the cancer; using them together provided a meaningful benefit for patients whose disease had come back or no longer responded to previous treatment. Tecvayli used on its own was also shown to benefit patients whose multiple myeloma had come back or for whom treatment had not worked well enough after at least one previous treatment. Compared with standard treatments, patients on Tecvayli lived longer without their cancer getting worse and also lived longer overall. 

The European Medicines Agency therefore decided that Tecvayli’s benefits are greater than its risks and it can be authorised for use in the EU.

Tecvayli was originally given ‘conditional authorisation’. The authorisation was then switched to standard authorisation as the company had provided additional data requested by the Agency. 

The company that markets Tecvayli will provide patients and carers with a patient card explaining the signs and symptoms of cytokine release syndrome and when to seek urgent medical help. Patients should carry the card with them and show it to any healthcare professional involved in their treatment.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tecvayli have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tecvayli are continuously monitored. Suspected side effects reported with Tecvayli are carefully evaluated and any necessary action taken to protect patients.

Tecvayli received a conditional marketing authorisation valid throughout the EU on 23 August 2022. The conditional marketing authorisation was switched to a standard marketing authorisation on 20 August 2026.

български (BG) (158.08 KB - PDF)

Vis

español (ES) (142.68 KB - PDF)

Vis

čeština (CS) (158.13 KB - PDF)

Vis

dansk (DA) (140.09 KB - PDF)

Vis

Deutsch (DE) (146.41 KB - PDF)

Vis

eesti (ET) (137.56 KB - PDF)

Vis

ελληνικά (EL) (161.56 KB - PDF)

Vis

français (FR) (133.9 KB - PDF)

Vis

hrvatski (HR) (156.58 KB - PDF)

Vis

italiano (IT) (139.73 KB - PDF)

Vis

latviešu (LV) (165.01 KB - PDF)

Vis

lietuvių (LT) (157.74 KB - PDF)

Vis

magyar (HU) (158.26 KB - PDF)

Vis

Malti (MT) (160.38 KB - PDF)

Vis

Nederlands (NL) (140.2 KB - PDF)

Vis

polski (PL) (157.54 KB - PDF)

Vis

português (PT) (142.82 KB - PDF)

Vis

română (RO) (156.26 KB - PDF)

Vis

slovenčina (SK) (156.88 KB - PDF)

Vis

slovenščina (SL) (156.82 KB - PDF)

Vis

suomi (FI) (138.51 KB - PDF)

Vis

svenska (SV) (129.37 KB - PDF)

Vis

Product information

български (BG) (664.19 KB - PDF)

Vis

español (ES) (525.69 KB - PDF)

Vis

čeština (CS) (807.12 KB - PDF)

Vis

dansk (DA) (980.41 KB - PDF)

Vis

Deutsch (DE) (627.88 KB - PDF)

Vis

eesti (ET) (727.76 KB - PDF)

Vis

ελληνικά (EL) (940.62 KB - PDF)

Vis

français (FR) (833.28 KB - PDF)

Vis

hrvatski (HR) (797.71 KB - PDF)

Vis

italiano (IT) (840.74 KB - PDF)

Vis

latviešu (LV) (757.4 KB - PDF)

Vis

lietuvių (LT) (753.38 KB - PDF)

Vis

magyar (HU) (560.95 KB - PDF)

Vis

Malti (MT) (832.79 KB - PDF)

Vis

Nederlands (NL) (527 KB - PDF)

Vis

polski (PL) (618.14 KB - PDF)

Vis

português (PT) (668.27 KB - PDF)

Vis

română (RO) (847.57 KB - PDF)

Vis

slovenčina (SK) (743.39 KB - PDF)

Vis

slovenščina (SL) (1.25 MB - PDF)

Vis

suomi (FI) (1001.24 KB - PDF)

Vis

svenska (SV) (932.05 KB - PDF)

Vis

Íslenska (IS) (942.28 KB - PDF)

Vis

norsk (NO) (1 MB - PDF)

Vis
Latest procedure affecting product information:VR/0000336274
22/10/2026
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (31.69 KB - PDF)

Vis

español (ES) (29.57 KB - PDF)

Vis

čeština (CS) (31.13 KB - PDF)

Vis

dansk (DA) (31.65 KB - PDF)

Vis

Deutsch (DE) (32.24 KB - PDF)

Vis

eesti (ET) (28.56 KB - PDF)

Vis

ελληνικά (EL) (30.84 KB - PDF)

Vis

français (FR) (29.58 KB - PDF)

Vis

hrvatski (HR) (30.25 KB - PDF)

Vis

italiano (IT) (29.58 KB - PDF)

Vis

latviešu (LV) (30.16 KB - PDF)

Vis

lietuvių (LT) (29.88 KB - PDF)

Vis

magyar (HU) (29.59 KB - PDF)

Vis

Malti (MT) (30.65 KB - PDF)

Vis

Nederlands (NL) (30.08 KB - PDF)

Vis

polski (PL) (31.09 KB - PDF)

Vis

português (PT) (30.82 KB - PDF)

Vis

română (RO) (29.99 KB - PDF)

Vis

slovenčina (SK) (30.95 KB - PDF)

Vis

slovenščina (SL) (30.05 KB - PDF)

Vis

suomi (FI) (28.7 KB - PDF)

Vis

svenska (SV) (29.7 KB - PDF)

Vis

Íslenska (IS) (30.03 KB - PDF)

Vis

norsk (NO) (30.94 KB - PDF)

Vis

Product details

Name of medicine
Tecvayli
International non-proprietary name (INN) or common name
teclistamab
Therapeutic area (MeSH)
Multiple Myeloma
Anatomical therapeutic chemical (ATC) code
L01FX24

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Tecvayli is indicated

  • in combination with daratumumab for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy  
  • as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. 

Authorisation details

EMA product number
EMEA/H/C/005865

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see PRIME: priority medicines.

Opinion adopted
21/07/2022
Marketing authorisation issued
23/08/2022
Revision
11

Assessment history

This page was last updated on

Share this page